Neprilysin inhibition, endorphin dynamics, and early symptomatic improvement in heart failure: a pilot study

AIM: Sacubitril/valsartan is a first‐in‐class angiotensin receptor‐neprilysin inhibitor developed for the treatment of heart failure with reduced ejection fraction. Its benefits are achieved through the inhibition of neprilysin (NEP) and the specific blockade of the angiotensin receptor AT1. The man...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:ESC Heart Fail
Main Authors: Revuelta‐López, Elena, Núñez, Julio, Gastelurrutia, Paloma, Cediel, Germán, Januzzi, James L., Ibrahim, Nasrien E., Emdin, Michele, VanKimmenade, Roland, Pascual‐Figal, Domingo, Núñez, Eduardo, Gommans, Frank, Lupón, Josep, Bayés‐Genís, Antoni
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Original Research Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7160502/
https://ncbi.nlm.nih.gov/pubmed/32045114
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ehf2.12607
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados